Drug Profile
INT 5A2
Alternative Names: INT-5A2Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator InteRNA Technologies
- Class Antineoplastics; MicroRNAs
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Liver cancer; Malignant melanoma
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Solid-tumours in Netherlands
- 28 Aug 2020 No recent reports of development identified for preclinical development in Liver-cancer in Netherlands
- 28 Aug 2020 No recent reports of development identified for preclinical development in Malignant-melanoma in Netherlands